![]() |
½ÃÀ庸°í¼
»óÇ°ÄÚµå
1579856
¼¼°èÀÇ À¯¹æ¾Ï ½ºÅ©¸®´× °Ë»ç ½ÃÀå ±Ô¸ð Á¶»ç, Áø´Ü °Ë»ç À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Breast Cancer Screening Tests Market Size Study, by Diagnostics Test Type, by End User, and Regional Forecasts 2022-2032. |
¼¼°èÀÇ À¯¹æ¾Ï ½ºÅ©¸®´× °Ë»ç ½ÃÀåÀº 2023³â¿¡´Â ¾à 29¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024-2032³â¿¡´Â 54.3%ÀÇ °ÇÀüÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
À¯¹æ¾Ï ½ºÅ©¸®´× °Ë»ç´Â Á¶±â ¹ß°ß¿¡ ÇʼöÀûÀ̸ç, Áõ»óÀÌ ³ªÅ¸³ª±â Àü¿¡ Áúº´À» ½Äº°ÇÒ ¼ö ÀÖÀ¸¸ç, Ä¡·á °á°ú¿Í »ýÁ¸À²À» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä °ËÁø ¹æ¹ýÀ¸·Î´Â À¯¹æ ÃÔ¿µ¼ú, ÀÓ»ó À¯¹æ °Ë»ç, À¯ÀüÀÚ °Ë»ç µîÀÌ ÀÖÀ¸¸ç, °¢°¢ À¯¹æ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â °íÀ¯ÇÑ Áø´ÜÀû ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù. À¯¹æ¾Ï¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ µðÁöÅÐ À¯¹æÃÔ¿µ¼ú ¹× 3D À¯¹æ ¿µ»ó°ú °°Àº °ËÁø ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ¼¼°è ½ÃÀåÀ» °ÈÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿©¼ºµéÀÇ ÀÏ»óÀûÀÎ °ËÁøÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ±¸»ó°ú ÀÎ½Ä Á¦°í Ä·ÆäÀÎÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ÇÎÅ©¸®º» Ä·ÆäÀΰú ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ ¼¼°è À¯¹æ¾Ï ±¸»ó°ú °°Àº ÇÁ·Î±×·¥Àº À¯¹æ¾Ï¿¡ ´ëÇÑ ÀνÄÀ» Å©°Ô Çâ»ó½ÃÅ°°í À¯¹æ¾Ï °ËÁøÀ» Àü ¼¼°è¿¡¼ ´õ ½±°Ô Á¢ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ BRCA À¯ÀüÀÚ °Ë»ç¿Í °°Àº °³ÀÎ ¸ÂÃãÇü Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»ç´Â À¯¹æ¾Ï¿¡ °É¸± È®·üÀ» ÆľÇÇÏ´Â µ¥ µµ¿òÀÌ µÉ »Ó¸¸ ¾Æ´Ï¶ó ȯÀÚ¿Í ÀÇ·á Àü¹®°¡°¡ ¿¹¹æ Á¶Ä¡¸¦ ÃëÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© Á¶±â ¹ß°ßÀÇ ¹üÀ§¸¦ ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°è¿¡¼ »óȯ »óȲÀÌ °³¼±µÇ°í ÀÖÀ¸¸ç, ƯÈ÷ ºÏ¹Ì¿Í °°Àº ½ÅÈï ½ÃÀå¿¡¼ ÀϺΠÀÇ·á º¸ÇèÀÌ Á¤±â °ËÁø ºñ¿ëÀ» º¸ÀåÇϱ⠽ÃÀÛÇÏ¸é¼ ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈÇÏ°í ÀÖ½À´Ï´Ù.
½ÃÀåÀº Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖÁö¸¸, ÷´Ü Áø´Ü °Ë»ç¿¡ µû¸¥ ³ôÀº ºñ¿ë, °úÀ× Áø´Ü¿¡ ´ëÇÑ ¿ì·Á, ¹ÐÁýµÈ À¯¼± Á¶Á÷ÀÌ Àִ ȯÀÚ¿¡¼ ±âÁ¸ ¼±º°°Ë»ç ¹æ¹ýÀÇ ÇÑ°è µî ¸î °¡Áö °úÁ¦µµ ³²¾ÆÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í »õ·Î¿î ½ºÅ©¸®´× ±â¼ú¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖÀ¸¸ç, Áø´Ü Åø¿¡ ÀΰøÁö´ÉÀ» ÅëÇÕÇÏ´Â °ÍÀº ½ÃÀå °ü°èÀڵ鿡°Ô Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
ºÏ¹Ì´Â ÇöÀç À¯¹æ¾Ï °ËÁø °Ë»ç ½ÃÀåÀ» µ¶Á¡ÇÏ°í ÀÖÀ¸¸ç, ±× ÁÖ¿ä ÀÌÀ¯´Â Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó, Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ±â¼úÀÇ ´«ºÎ½Å ¹ßÀü¿¡ ±âÀÎÇÕ´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÅõÀÚ Áõ°¡, °ËÁø ÇÁ·Î±×·¥ Á¢±Ù¼º Çâ»ó, Áß±¹ ¹× Àεµ¿Í °°Àº ±¹°¡µéÀÇ ÀÎ½Ä Á¦°í ±¸»ó Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Global Breast Cancer Screening Tests Market was valued at approximately USD 2.93 billion in 2023 and is projected to grow with a healthy CAGR of 54.3% over the forecast period 2024-2032. Breast cancer screening tests are critical for early detection, potentially identifying the disease before symptoms manifest, which greatly improves treatment outcomes and survival rates. Key screening tools include mammography, clinical breast exams, and genetic testing, each providing unique diagnostic insights to aid in the early detection of breast cancer. Rising awareness about breast cancer, coupled with advancements in screening technology, such as digital mammography and 3D breast imaging, has bolstered the global market. Furthermore, the increasing number of government initiatives and awareness campaigns that encourage routine screening among women is a significant factor driving market growth. Programs like the Pink Ribbon campaign, as well as WHO's Global Breast Cancer Initiative, have significantly improved awareness, making breast cancer screening more accessible worldwide.
Moreover, the demand for personalized diagnostic tools, such as BRCA genetic testing, has surged due to the growing emphasis on personalized medicine. Genetic testing not only helps in identifying susceptibility to breast cancer but also enables patients and healthcare professionals to take preventive measures, thereby enhancing the scope of early detection. The reimbursement landscape has also improved globally, especially in developed regions like North America, where several healthcare plans now cover routine screening costs, further accelerating market growth.
While the market shows substantial promise, several challenges remain, such as high costs associated with advanced diagnostic tests, overdiagnosis concerns, and the limitations of traditional screening methods in patients with dense breast tissue. Nonetheless, ongoing research into new screening technologies and the integration of artificial intelligence in diagnostic tools are expected to provide significant growth opportunities for market players.
The North American region currently dominates the breast cancer screening tests market, primarily due to a well-established healthcare infrastructure, increasing awareness of early detection, and significant advancements in diagnostic technology. In contrast, the Asia-Pacific region is projected to exhibit the highest growth rate, driven by rising healthcare investments, improved accessibility to screening programs, and growing awareness initiatives in countries like China and India.